WHO clears Cervarix for developing world

GlaxoSmithKline has cleared a key hurdle for gaining wider use of its cervical cancer vaccine Cervarix, winning the World Health Organization's approval to offer the jab in developing countries. That official green light is a prerequisite for non-profit groups like GAVI as well as UN agencies that want to buy the vaccine. Cervarix report

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.